2019 ASCO GU Symposium

2019 ASCO GU Symposium

INTERVIEW WITH SUSAN HALABI
Racial Disparities in Prostate Cancer Treatment and Outcomes

VIEW ALL PROSTATE CANCER VIDEOS

2019 ASCO GU Symposium

2019 ASCO GU Symposium

INTERVIEW WITH MICHAEL HOFMAN
Theranostic Approaches for Advanced Prostate Cancer

VIEW ALL IMAGING: PROSTATE VIDEOS

2019 ASCO GU Symposium

2019 ASCO GU Symposium

INTERVIEW WITH KARIM FIZAZI
ARAMIS - Efficacy and Safety of Darolutamide in nmCRPC

VIEW ALL nmCRPC VIDEOS

2019 ASCO GU Symposium

2019 ASCO GU Symposium

INTERVIEW WITH MATTHEW GALSKY
Combination Approaches with Immune-Checkpoint Blockade in Bladder Cancer

VIEW ALL BLADDER CANCER VIDEOS

Featured Videos

#AUA14 - Poster: Overactive bladder patients ≥ 65 years of age have a similar efficacy and safety profile with onabotulinumtoxinA as patients less than 65 years of age

ORLANDO, FL USA (UroToday.com) - Presented by Courtenay Moore,1 Albert Kaufmann,2 Manher Joshi,3 Christopher Nardo,3 Yan Zheng,4 and Sender Herschorn5 at the American Urological Association (AUA) Annual Meeting - May 16 - 21, 2014 - Orlando, Florida USA

aua 2014 moore age poster thumb

1Cleveland Clinic, Cleveland, OH, USA; 2Kliniken Maria Hilf GmbH, Mönchengladbach, Germany; 3Allergan, Inc., Irvine, CA, USA; 4Allergan, Inc., Bridgewater, NJ, USA; 5University of Toronto, Toronto, ON, Canada

 

 

Conference Coverage
 
Recent data from conferences worldwide
Journals
Publications focusing on urologic cancer treatments through original manuscripts
Everyday Urology Volume 3 Issue 4

Everyday Urology™ - Oncology Insights

PCAN cover

Prostate Cancer and Prostatic Diseases

From the Editor

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe